Neurology
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases
Feigin, A. et al.
Expert Opin Investig Drugs 2025, Vol. 34, No. 3, 109–119
Zauderer, M. & Evans, E.
Clin Transl Med. 2023 Feb;13(2)
Feigin, A. et al.
Nature Medicine, Aug08,2022
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
Evans, E. et al.
J Neuroinflammation 19, 200 (2022)
Mao, Y. et al.
Int. J. Mol. Sci. 2021, 22, 9465
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.
LaGanke, C. et al.
Neurol Neuroimmunol Neuroinflamm 2017. 4: e367.
Southwell, A.L. et al.
Neurobiol Dis. 2015 Feb 3; 76
Smith, E. et al.
Neurobiol Dis. 2014 Oct 18;73C
Oncology
Melanoma Paper
Ruffin, A. et al.
Pending
Garg, S. et al.
Cell Reports 45, 117050. 2026
Greengard, E. et al.
Pediatr Blood Cancer. 2024; 71
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Shafique, M.R. et al.
Clinical Cancer Research, 2021
Clavijo, P.E. et al.
Cancer Immunol Res. 2019;7(2)
Evans E.E. et al.
Cancer Immunol Res. 2015
Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D
Evans, E.E. et al.
Invited “Author’s View”. OncoImmunology, 2015. 4:12
Patnaik, A. et al.
Clin Cancer Res. 2016;22(4)
Nonclinical & Bioanalytical
Nonclinical Safety Evaluation of VX15/2503 a Humanized IgG4 Anti-SEMA4D Antibody
Leonard, J. et al.
Mol Cancer Ther; 14(4) April 2015
Saturation Monitoring of VX15/2503, a Novel Semaphorin 4D-Specific Antibody, in Clinical Trials
Fisher, T. et al.
Cytometry Part B (Clinical Cytometry) 90B:199–208 (2016)
Generation and preclinical characterization of an antibody specific for SEMA4D
Fisher, T. et al.
mAbs 8:1, 150-162; January 2016
ActivMab
Learn more about how our ActivMab technology can help with Antibody Discovery
Use of poxvirus display to select antibodies specific for complex membrane antigens
Smith, S. et al.
MABS2023, VOL. 15, NO. 1, 2249947
A Vaccinia-based system for directed evolution of GPCRs in mammalian cells
Klenk, C. et al.
Nature Communications| (2023) 14:1770
Smith, E. & Zauderer, M.
Curr Drug Discov Technol. 2014 Mar;11(1):48-55.
Antibody Selection from Immunoglobulin Libraries Expressed in Mammalian Cells
Smith, S. & Zauderer, M.
In Therapeutic Antibodies: From Bench to Clinic, 2009
Coppage, M. et al.
Leuk Res. 2007;31(2):195-202
Construction of cDNA Libraries in Vaccinia Virus
Smith, E. et al.
Methods Mol Biol. 2004;269:65-76.
Smith, S. et al
Nat Med. 2001;7(8):967-972
Construction and characterization of vaccinia direct ligation vectors
Merchlinsky, M. et al
Virology. 1997;238(2):444-451
CXCL13 & NKT
CXCL13 Antibody for the treatment of autoimmune disorders
Klimatcheva, E. et al
BMC Immunol. 2015;16(1):6
Yamamoto, K. et al
Mucosal Immunol. 2014;7(5):1244-1254
Corgnac, S. et al
Cancer Immunol Immunother. 2013;62(4):747-760
Stirnemann, K. et al
J Clin Invest. 2008;118(3)